comparemela.com

Ascelia Pharma meets major milestone with patient enrollment completion of Phase 3 Study for Orviglance, novel MRI contrast agent for patients with kidney impairment

BioPharma

Related Keywords

Sweden ,Japan ,Ukraine ,Magnus Corfitzen ,Ascelia Pharma ,Drug Administration ,Orphan Drug Designation ,Nephrogenic Systemic Fibrosis ,New Drug Application ,

comparemela.com © 2020. All Rights Reserved.